{"DataElement":{"publicId":"7391923","version":"1","preferredName":"Protocol Administered Pegaspargase Yes No Not Prescribed Indicator","preferredDefinition":"The response to a question asking whether a patient received Pegaspargase if prescribed by the protocol.","longName":"PROT_ADMIN_PEG_IND","context":"COG","contextVersion":"1","DataElementConcept":{"publicId":"7391920","version":"1","preferredName":"Pegaspargase Protocol Administered","preferredDefinition":"A complex of polyethylene glycol conjugated with L-asparaginase.  Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)_A rule which guides how an activity should be performed._The act of having given something (e.g., a medication or test).","longName":"7391860v1.0:2991412v1.0","context":"COG","contextVersion":"1","ObjectClass":{"publicId":"7391860","version":"1","preferredName":"Pegaspargase","preferredDefinition":"A complex of polyethylene glycol conjugated with L-asparaginase.  Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)","longName":"C1200","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Pegaspargase","conceptCode":"C1200","definition":"A complex of polyethylene glycol conjugated with L-asparaginase.  Asparaginase hydrolyzes L-asparagine to L-aspartic acid and ammonia, thereby depleting these cells of asparagine and blocking protein synthesis and tumor cell proliferation, especially in the G1 phase of the cell cycle.  The agent also induces apoptosis in tumor cells. Pegylation decreases the enzyme's antigenicity. Asparagine is critical to protein synthesis in leukemic cells, which cannot synthesize this amino acid due to the absence of the enzyme asparagine synthase. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACC9791F-8A7D-4343-E053-4EBD850AD386","latestVersionIndicator":"Yes","beginDate":"2020-08-13","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-08-13","modifiedBy":"ONEDATA","dateModified":"2020-08-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2991412","version":"1","preferredName":"Protocol Administered","preferredDefinition":"A protocol is a rule which guides how an activity should be performed; a set of formal rules used to specify the format of an exchange of data.:Given.","longName":"C42651:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protocol","conceptCode":"C42651","definition":"A rule which guides how an activity should be performed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7DB42D06-551A-0AC4-E040-BB89AD436DB2","latestVersionIndicator":"Yes","beginDate":"2010-01-21","endDate":null,"createdBy":"WHITES","dateCreated":"2010-01-21","modifiedBy":"ONEDATA","dateModified":"2010-01-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACCB1CE8-88ED-4E59-E053-4EBD850A218D","latestVersionIndicator":"Yes","beginDate":"2020-08-13","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-08-13","modifiedBy":"SETRAKIN","dateModified":"2020-08-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7391921","version":"1","preferredName":"Pegaspargase Yes No Not Prescribed Indicator","preferredDefinition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"7391921v1.0","context":"COG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"55","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Not applicable","valueDescription":"N/A, not prescribed by protocol this reporting period","ValueMeaning":{"publicId":"7391922","version":"1","preferredName":"N/A, not prescribed by protocol this reporting period","longName":"7391922","preferredDefinition":"N/A, not prescribed by protocol this reporting period","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACCB35CD-4C50-56BA-E053-4EBD850AD349","latestVersionIndicator":"Yes","beginDate":"2020-08-13","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-08-13","modifiedBy":"ONEDATA","dateModified":"2020-08-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ACCB35CD-4C69-56BA-E053-4EBD850AD349","beginDate":"2020-08-13","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-08-13","modifiedBy":"ONEDATA","dateModified":"2020-08-13","deletedIndicator":"No"},{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"3382682","version":"1","preferredName":"No","longName":"3382682","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B99068EB-6AAA-AE1D-E040-BB89AD4362C9","latestVersionIndicator":"Yes","beginDate":"2012-02-22","endDate":null,"createdBy":"PATELV","dateCreated":"2012-02-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ACCB35CD-4C73-56BA-E053-4EBD850AD349","beginDate":"2020-08-13","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-08-13","modifiedBy":"ONEDATA","dateModified":"2020-08-13","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"3197153","version":"1","preferredName":"Yes","longName":"3197153v1.00","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D865DE5-558A-1AC9-E040-BB89AD436B4F","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2011-03-02","modifiedBy":"SOKKERL","dateModified":"2023-12-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"ACCB35CD-4C7D-56BA-E053-4EBD850AD349","beginDate":"2020-08-13","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-08-13","modifiedBy":"ONEDATA","dateModified":"2020-08-13","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2320047","version":"1","preferredName":"Indicator","preferredDefinition":"An event, entity or condition that typically characterizes a prescribed environment or situation. Indicators determine or aid in determining whether or not certain stated circumstances exist or criteria are satisfied. (On-line Medical Dictionary)","longName":"C25180","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"FC6EF0D8-521A-6865-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-25","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-07-25","modifiedBy":"ONEDATA","dateModified":"2005-07-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACCB35CD-4C39-56BA-E053-4EBD850AD349","latestVersionIndicator":"Yes","beginDate":"2020-08-13","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-08-13","modifiedBy":"SETRAKIN","dateModified":"2020-08-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"If prescribed by protocol, di","type":"Preferred Question Text","description":"If prescribed by protocol, did patient receive Pegaspargase during this Reporting Period?","url":null,"context":"COG"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"If prescribed by protocol, did patient receive Pegaspargase/Calaspargase during this Reporting Period?","url":null,"context":"COG"},{"name":"COG CRF Text 03","type":"Alternate Question Text","description":"Did patient receive Pegaspargase during this Reporting Period?","url":null,"context":"COG"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Did patient receive Pegaspargase/Calaspargase during this Reporting Period?","url":null,"context":"COG"}],"origin":"COG CRF:Children's Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACCB3DA5-784C-5992-E053-4EBD850AD90E","latestVersionIndicator":"Yes","beginDate":"2020-08-13","endDate":null,"createdBy":"SETRAKIN","dateCreated":"2020-08-13","modifiedBy":"KUMMEROA","dateModified":"2022-10-20","changeDescription":null,"administrativeNotes":"2022.10.20 AQT added per ticket request CADSR0001615. ak","unresolvedIssues":null,"deletedIndicator":"No"}}